Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration

Achiron, A., Givon, U., Magalashvili, D., Dolev, M., Liraz Zaltzman, S., Kalron, A., et al. (2015). Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Multiple Sclerosis Journal, 21(6), 767–775. https://doi.org/10.1177/1352458514554053.PubMedCrossRef

Amano, S., Arai, M., Goto, S., & Togari, A. (2007). Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochimica et Biophysica Acta, 1770(6), 966–973. https://doi.org/10.1016/j.bbagen.2007.02.009.PubMedCrossRef

Anlar, O. (2009). Treatment of multiple sclerosis. CNS & Neurological Disorders: Drug Targets, 8(3), 167–174.CrossRef

Atchison, D. K., Harding, P., & Beierwaltes, W. H. (2013). Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and beta-adrenergic activity. American Journal of Physiology. Renal Physiology, 305(8), F1109–F1117. https://doi.org/10.1152/ajprenal.00010.2013.PubMedPubMedCentralCrossRef

Ayuso, T., Aznar, P., Soriano, L., Olaskoaga, A., Roldan, M., Otano, M., et al. (2017). Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis. PLoS ONE, 12(3), e0174726. https://doi.org/10.1371/journal.pone.0174726.PubMedPubMedCentralCrossRef

Baidina, T. V., Akintseva Iu, V., & Trushnikova, T. N. (2014). A chronic fatigue syndrome and blood platelet serotonin levels in patients with multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova, 114(2 Pt 2), 25–28.

Bajayo, A., Bar, A., Denes, A., Bachar, M., Kram, V., Attar-Namdar, M., et al. (2012). Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proceedings of the National Academy of Sciences USA, 109(38), 15455–15460. https://doi.org/10.1073/pnas.1206061109.CrossRef

Baldock, P. A., Allison, S. J., Lundberg, P., Lee, N. J., Slack, K., Lin, E. J., et al. (2007). Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. Journal of Biological Chemistry, 282(26), 19092–19102. https://doi.org/10.1074/jbc.M700644200.PubMedCrossRef

Baldock, P. A., Lee, N. J., Driessler, F., Lin, S., Allison, S., Stehrer, B., et al. (2009). Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS ONE, 4(12), e8415. https://doi.org/10.1371/journal.pone.0008415.PubMedPubMedCentralCrossRef

Baldock, P. A., Sainsbury, A., Allison, S., Lin, E. J., Couzens, M., Boey, D., et al. (2005). Hypothalamic control of bone formation: Distinct actions of leptin and y2 receptor pathways. Journal of Bone and Mineral Research, 20(10), 1851–1857. https://doi.org/10.1359/JBMR.050523.PubMedCrossRef

Baldock, P. A., Sainsbury, A., Couzens, M., Enriquez, R. F., Thomas, G. P., Gardiner, E. M., et al. (2002). Hypothalamic Y2 receptors regulate bone formation. The Journal of Clinical Investigation, 109(7), 915–921. https://doi.org/10.1172/JCI14588.PubMedPubMedCentralCrossRef

Bedoui, S., Lechner, S., Gebhardt, T., Nave, H., Beck-Sickinger, A. G., Straub, R. H., et al. (2002). NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: Sympathetic co-transmission during leukocyte mobilization. Journal of Neuroimmunology, 132(1–2), 25–33.PubMedCrossRef

Bedoui, S., Miyake, S., Lin, Y., Miyamoto, K., Oki, S., Kawamura, N., et al. (2003). Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. The Journal of Immunology, 171(7), 3451–3458.PubMedCrossRef

Bharne, A. P., Upadhya, M. A., Shelkar, G. P., Singru, P. S., Subhedar, N. K., & Kokare, D. M. (2013). Neuroprotective effect of cocaine- and amphetamine-regulated transcript peptide in spinal cord injury in mice. Neuropharmacology, 67, 126–135. https://doi.org/10.1016/j.neuropharm.2012.10.028.PubMedCrossRef

Bischoff-Ferrari, H. A., Willett, W. C., Wong, J. B., Stuck, A. E., Staehelin, H. B., Orav, E. J., et al. (2009). Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Archives of Internal Medicine, 169(6), 551–561. https://doi.org/10.1001/archinternmed.2008.600.PubMedCrossRef

Boden, G., Chen, X., Mozzoli, M., & Ryan, I. (1996). Effect of fasting on serum leptin in normal human subjects. Journal of Clinical Endocrinology and Metabolism, 81(9), 3419–3423. https://doi.org/10.1210/jcem.81.9.8784108.PubMed

Bonnet, N., Gadois, C., McCloskey, E., Lemineur, G., Lespessailles, E., Courteix, D., et al. (2007). Protective effect of beta blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 40(5), 1209–1216. https://doi.org/10.1016/j.bone.2007.01.006.PubMedCrossRef

Bradburn, S., McPhee, J. S., Bagley, L., Sipila, S., Stenroth, L., Narici, M. V., et al. (2016). Association between osteocalcin and cognitive performance in healthy older adults. Age and Ageing, 45(6), 844–849. https://doi.org/10.1093/ageing/afw137.PubMedPubMedCentralCrossRef

Burguera, B., Couce, M. E., Long, J., Lamsam, J., Laakso, K., Jensen, M. D., et al. (2000). The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. Neuroendocrinology, 71(3), 187–195.PubMedCrossRef

Calvi, L. M., Sims, N. A., Hunzelman, J. L., Knight, M. C., Giovannetti, A., Saxton, J. M., et al. (2001). Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. The Journal of Clinical Investigation, 107(3), 277–286. https://doi.org/10.1172/JCI11296.PubMedPubMedCentralCrossRef

Carvalho, A. F., Rocha, D. Q., McIntyre, R. S., Mesquita, L. M., Kohler, C. A., Hyphantis, T. N., et al. (2014). Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. Journal of Psychiatric Research, 59, 28–37. https://doi.org/10.1016/j.jpsychires.2014.08.002.PubMedCrossRef

Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., et al. (2007). The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain, 130(Pt 10), 2543–2553. https://doi.org/10.1093/brain/awm160.PubMedCrossRef

Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C., Rittling, S. R., Denhardt, D. T., et al. (2001). The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science, 294(5547), 1731–1735. https://doi.org/10.1126/science.1062960.PubMedCrossRef

Chelmicka-Schorr, E., Checinski, M., & Arnason, B. G. (1988). Chemical sympathectomy augments the severity of experimental allergic encephalomyelitis. Journal of Neuroimmunology, 17(4), 347–350.PubMedCrossRef

Chelmicka-Schorr, E., Kwasniewski, M. N., Thomas, B. E., & Arnason, B. G. (1989). The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats. Journal of Neuroimmunology, 25(2–3), 203–207.PubMedCrossRef

Comabella, M., Pericot, I., Goertsches, R., Nos, C., Castillo, M., Blas Navarro, J., et al. (2005). Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology, 158(1–2), 231–239. https://doi.org/10.1016/j.jneuroim.2004.09.004.PubMedCrossRef

Constantinescu, C. S., Niepel, G., Patterson, M., Judd, A., Braitch, M., Fahey, A. J., et al. (2011). Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: No correlation with fatigue and sleepiness. Journal of the Neurological Sciences, 307(1–2), 127–131. https://doi.org/10.1016/j.jns.2011.04.024.PubMedCrossRef

Cosman, F., Nieves, J., Komar, L., Ferrer, G., Herbert, J., Formica, C., et al. (1998). Fracture history and bone loss in patients with MS. Neurology, 51(4), 1161–1165.PubMedCrossRef

Cosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., et al. (2001). Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. Journal of Bone and Mineral Research, 16(5), 925–931. https://doi.org/10.1359/jbmr.2001.16.5.925.PubMedCrossRef

Crespi, F. (2011). Influence of Neuropeptide Y and antidepressants upon cerebral monoamines involved in depression: An in vivo electrochemical study. Brain Research, 1407, 27–37. https://doi.org/10.1016/j.brainres.2011.05.033.PubMedCrossRef

Dalvi, P. S., Chalmers, J. A., Luo, V., Han, D. Y., Wellhauser, L., Liu, Y., et al. (2017). High fat induces acute and chronic inflammation in the hypothalamus: Effect of high-fat diet, palmitate and TNF-alpha on appetite-regulating NPY neurons. International Journal of Obesity (London), 41(1), 149–158. https://doi.org/10.1038/ijo.2016.183.CrossRef

de Jong, W. H., de Vries, E. G., & Kema, I. P. (2009). Serotonin rising. New England Journal of Medicine, 360(24), 2580–2581. (author reply 2581–2582).PubMedCrossRef

Di Filippo, M., Pini, L. A., Pelliccioli, G. P., Calabresi, P., & Sarchielli, P. (2008). Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 79(11), 1224–1229. https://doi.org/10.1136/jnnp.2007.139071.PubMedCrossRef

Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Batkai, S., Jarai, Z., et al. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410(6830), 822–825. https://doi.org/10.1038/35071088.PubMedCrossRef

Dovio, A., Perazzolo, L., Osella, G., Ventura, M., Termine, A., Milano, E., et al. (2004). Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism, 89(10), 4923–4928. https://doi.org/10.1210/jc.2004-0164.PubMedCrossRef

Duarte-Neves, J., Pereira de Almeida, L., & Cavadas, C. (2016). Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. Neurobiology of Diseases, 95, 210–224. https://doi.org/10.1016/j.nbd.2016.07.022.CrossRef

Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., et al. (2005). Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature, 434(7032), 514–520. https://doi.org/10.1038/nature03398.PubMedCrossRef

Esler, M., Vaz, M., Collier, G., Nestel, P., Jennings, G., Kaye, D., et al. (1998). Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet, 351(9106), 879. https://doi.org/10.1016/S0140-6736(05)70289-0.PubMedCrossRef

Evequoz, D., Grouzmann, E., Nussberger, J., Niederberger, M., Brunner, H. R., & Waeber, B. (1995). Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats. Regulatory Peptides, 58(3), 163–166.PubMedCrossRef

Fasshauer, M., Kralisch, S., Klier, M., Lossner, U., Bluher, M., Klein, J., et al. (2003). Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 301(4), 1045–1050.PubMedCrossRef

Fernandes, B. S., Hodge, J. M., Pasco, J. A., Berk, M., & Williams, L. J. (2016). Effects of depression and serotonergic antidepressants on bone: Mechanisms and Implications for the treatment of depression. Drugs and Aging, 33(1), 21–25. https://doi.org/10.1007/s40266-015-0323-4.PubMedCrossRef

Flachenecker, P., Reiners, K., Krauser, M., Wolf, A., & Toyka, K. V. (2001). Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Multiple Sclerosis Journal, 7(5), 327–334.PubMedCrossRef

Flachenecker, P., Rufer, A., Bihler, I., Hippel, C., Reiners, K., Toyka, K. V., et al. (2003). Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology, 61(6), 851–853.PubMedCrossRef

Flachenecker, P., Wolf, A., Krauser, M., Hartung, H. P., & Reiners, K. (1999). Cardiovascular autonomic dysfunction in multiple sclerosis: Correlation with orthostatic intolerance. Journal of Neurology, 246(7), 578–586.PubMedCrossRef

Frisullo, G., Mirabella, M., Angelucci, F., Caggiula, M., Morosetti, R., Sancricca, C., et al. (2007). The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 192(1–2), 174–183. https://doi.org/10.1016/j.jneuroim.2007.08.008.PubMedCrossRef

Fry, M., Smith, P. M., Hoyda, T. D., Duncan, M., Ahima, R. S., Sharkey, K. A., et al. (2006). Area postrema neurons are modulated by the adipocyte hormone adiponectin. Journal of Neuroscience, 26(38), 9695–9702. https://doi.org/10.1523/JNEUROSCI.2014-06.2006.PubMedCrossRef

Gallai, V., Sarchielli, P., Firenze, C., Trequattrini, A., Paciaroni, M., Usai, F., et al. (1994). Neuropeptide Y plasma levels and serum dopamine-beta-hydroxylase activity in MS patients with and without abnormal cardiovascular reflexes. Acta Neurologica Belgica, 94(1), 44–52.PubMed

Giorelli, M., Livrea, P., & Trojano, M. (2004). Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. Journal of Neuroimmunology, 155(1–2), 143–149. https://doi.org/10.1016/j.jneuroim.2004.05.013.PubMedCrossRef

Grzeda, E., Schlicker, E., Luczaj, W., Harasim, E., Baranowska-Kuczko, M., & Malinowska, B. (2015). Bi-directional CB1 receptor-mediated cardiovascular effects of cannabinoids in anaesthetized rats: Role of the paraventricular nucleus. Journal of Physiology and Pharmacology, 66(3), 343–353.PubMed

Gulli, G., Cevese, A., Cappelletto, P., Gasparini, G., & Schena, F. (2003). Moderate aerobic training improves autonomic cardiovascular control in older women. Clinical Autonomic Research, 13(3), 196–202. https://doi.org/10.1007/s10286-003-0090-x.PubMed

Hanyu, R., Wehbi, V. L., Hayata, T., Moriya, S., Feinstein, T. N., Ezura, Y., et al. (2012). Anabolic action of parathyroid hormone regulated by the beta2-adrenergic receptor. Proceedings of the National Academy of Sciences USA, 109(19), 7433–7438. https://doi.org/10.1073/pnas.1109036109.CrossRef

Haug, S. R., Brudvik, P., Fristad, I., & Heyeraas, K. J. (2003). Sympathectomy causes increased root resorption after orthodontic tooth movement in rats: Immunohistochemical study. Cell and Tissue Research, 313(2), 167–175. https://doi.org/10.1007/s00441-003-0753-x.PubMedCrossRef

Hauschka, P. V., Lian, J. B., Cole, D. E., & Gundberg, C. M. (1989). Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiological Reviews, 69(3), 990–1047.PubMedCrossRef

He, J. Y., Zheng, X. F., Jiang, S. D., Chen, X. D., & Jiang, L. S. (2013). Sympathetic neuron can promote osteoblast differentiation through BMP signaling pathway. Cellular Signalling, 25(6), 1372–1378. https://doi.org/10.1016/j.cellsig.2013.02.016.PubMedCrossRef

Hearn, A. P., & Silber, E. (2010). Osteoporosis in multiple sclerosis. Multiple Sclerosis Journal, 16(9), 1031–1043. https://doi.org/10.1177/1352458510368985.PubMedCrossRef

Hesse, S., Moeller, F., Petroff, D., Lobsien, D., Luthardt, J., Regenthal, R., et al. (2014). Altered serotonin transporter availability in patients with multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 41(5), 827–835. https://doi.org/10.1007/s00259-013-2636-z.PubMedCrossRef

Hinoi, E., Gao, N., Jung, D. Y., Yadav, V., Yoshizawa, T., Myers, M. G., Jr., et al. (2008). The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. Journal of Cell Biology, 183(7), 1235–1242. https://doi.org/10.1083/jcb.200809113.PubMedPubMedCentralCrossRef

Hoang, D., Broer, N., Sosa, J. A., Abitbol, N., Yao, X., Li, F., et al. (2016). Leptin is produced by parathyroid glands and stimulates parathyroid hormone secretion. Annals of Surgery. https://doi.org/10.1097/SLA.0000000000002004.

Holmoy, T., Torkildsen, O., Myhr, K. M., & Loken-Amsrud, K. I. (2012). Vitamin D supplementation and monitoring in multiple sclerosis: Who, when and wherefore. Acta Neurologica Scandinavica. https://doi.org/10.1111/ane.12028.

Huang, J. C., Sakata, T., Pfleger, L. L., Bencsik, M., Halloran, B. P., Bikle, D. D., et al. (2004). PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research, 19(2), 235–244. https://doi.org/10.1359/JBMR.0301226.PubMedCrossRef

Hur, E. M., Youssef, S., Haws, M. E., Zhang, S. Y., Sobel, R. A., & Steinman, L. (2007). Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature Immunology, 8(1), 74–83. https://doi.org/10.1038/ni1415.PubMedCrossRef

Hwang, L. L., Chen, C. T., Li, T. L., Chiu, C. Z., & Chi, S. F. (2004). Central pressor effects of CART peptides in anesthetized rats. Neuropeptides, 38(2–3), 69–76. https://doi.org/10.1016/j.npep.2004.02.001.PubMedCrossRef

Iaffaldano, P., Ruggieri, M., Viterbo, R. G., Mastrapasqua, M., & Trojano, M. (2014). The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain, Behavior, and Immunity, 35, 176–181. https://doi.org/10.1016/j.bbi.2013.08.009.PubMedCrossRef

Ibrahimi, K., Danser, A., Terwindt, G. M., van den Meiracker, A. H., & MaassenVanDenBrink, A. (2017). A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan. Cephalalgia, 37(1), 94–98. https://doi.org/10.1177/0333102416637833.PubMedCrossRef

Idris, A. I., & Ralston, S. H. (2012). Role of cannabinoids in the regulation of bone remodeling. Frontiers in Endocrinology (Lausanne), 3, 136. https://doi.org/10.3389/fendo.2012.00136.

Imai, J., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Uno, K., et al. (2006). Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring), 14(7), 1132–1141. https://doi.org/10.1038/oby.2006.130.CrossRef

Jang, W., Park, J., Kim, J. S., Youn, J., Oh, E., Kwon, K. Y., et al. (2015). Vitamin D deficiency in Parkinson’s disease patients with orthostatic hypotension. Acta Neurologica Scandinavica, 132(4), 242–250. https://doi.org/10.1111/ane.12390.PubMedCrossRef

Joborn, H., Hjemdahl, P., Wide, L., Akerstrom, G., & Ljunghall, S. (1987). Reduction of serum parathyroid hormone levels during sympathetic stimulation in man. Journal of Endocrinological Investigation, 10(2), 153–156.PubMedCrossRef

Jones, L. F., & Tackett, R. L. (1988). Interaction of propranolol with central serotonergic neurons. Life Sciences, 43(26), 2249–2255.PubMedCrossRef

Jorde, R., Waterloo, K., Saleh, F., Haug, E., & Svartberg, J. (2006). Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromso study. Journal of Neurology, 253(4), 464–470. https://doi.org/10.1007/s00415-005-0027-5.PubMedCrossRef

Jost, W. H., & Augustis, S. (2014). Severity of orthostatic hypotension in the course of Parkinson’s disease: No correlation with the duration of the disease. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2014.12.016.

Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., & Tobe, K. (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of Clinical Investigation, 116(7), 1784–1792. https://doi.org/10.1172/JCI29126.PubMedPubMedCentralCrossRef

Kadriu, B., Gold, P. W., Luckenbaugh, D. A., Lener, M. S., Ballard, E. D., Niciu, M. J., et al. (2017). Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Molecular Psychiatry. https://doi.org/10.1038/mp.2017.109.PubMedPubMedCentral

Kajimura, D. (2013). Adiponectin regulates bone mass accrual through two opposite mechanisms, one local and one central, that both rely on FoxO1. Cell Metabolism, 17(6), 901–915.PubMedPubMedCentralCrossRef

Kalra, S. P., Dube, M. G., & Iwaniec, U. T. (2009). Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay. Peptides, 30(5), 967–973. https://doi.org/10.1016/j.peptides.2009.01.020.PubMedPubMedCentralCrossRef

Kamphuis, W. W., Derada Troletti, C., Reijerkerk, A., Romero, I. A., & de Vries, H. E. (2015). The blood-brain barrier in multiple sclerosis: MicroRNAs as key regulators. CNS & Neurological Disorders: Drug Targets, 14(2), 157–167.CrossRef

Kantarci, O., & Wingerchuk, D. (2006). Epidemiology and natural history of multiple sclerosis: New insights. Current Opinion in Neurology, 19(3), 248–254. https://doi.org/10.1097/01.wco.0000227033.47458.82.PubMedCrossRef

Kawamori, Y., Katayama, Y., Asada, N., Minagawa, K., Sato, M., Okamura, A., et al. (2010). Role for vitamin D receptor in the neuronal control of the hematopoietic stem cell niche. Blood, 116(25), 5528–5535. https://doi.org/10.1182/blood-2010-04-279216.PubMedCrossRef

Keaveny, T. M., Hoffmann, P. F., Singh, M., Palermo, L., Bilezikian, J. P., Greenspan, S. L., et al. (2008). Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. Journal of Bone and Mineral Research, 23(12), 1974–1982. https://doi.org/10.1359/jbmr.080805.PubMedPubMedCentralCrossRef

Kepczynska, K., Zajda, M., Lewandowski, Z., Przedlacki, J., & Zakrzewska-Pniewska, B. (2016). Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurologia i Neurochirurgia Polska, 50(4), 251–257. https://doi.org/10.1016/j.pjnns.2016.04.010.PubMedCrossRef

Kim, Y., Hamada, N., Takahashi, Y., Sasaguri, K., Tsukinoki, K., Onozuka, M., et al. (2009). Cervical sympathectomy causes alveolar bone loss in an experimental rat model. Journal of Periodontal Research, 44(6), 695–703. https://doi.org/10.1111/j.1600-0765.2008.01177.x.PubMedCrossRef

Klein-Nulend, J., van Oers, R. F., Bakker, A. D., & Bacabac, R. G. (2015). Bone cell mechanosensitivity, estrogen deficiency, and osteoporosis. Journal of Biomechanics, 48(5), 855–865. https://doi.org/10.1016/j.jbiomech.2014.12.007.PubMedCrossRef

Kodounis, A., Stamboulis, E., Constantinidis, T. S., & Liolios, A. (2005). Measurement of autonomic dysregulation in multiple sclerosis. Acta Neurologica Scandinavica, 112(6), 403–408. https://doi.org/10.1111/j.1600-0404.2005.00446.x.PubMedCrossRef

Kohli, S. S., & Kohli, V. S. (2011). Role of RANKL–RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian Journal of Endocrinology and Metabolism, 15(3), 175–181. https://doi.org/10.4103/2230-8210.83401.PubMedPubMedCentralCrossRef

Kohm, A. P., & Sanders, V. M. (2001). Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacological Reviews, 53(4), 487–525.PubMed

Kong, Y. Y., Boyle, W. J., & Penninger, J. M. (2000). Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunology Today, 21(10), 495–502.PubMedCrossRef

Koven, N. S., Cadden, M. H., Murali, S., & Ross, M. K. (2013). Vitamin D and long-term memory in multiple sclerosis. Cognitive and Behavioral Neurology, 26(3), 155–160. https://doi.org/10.1097/WNN.0000000000000009.PubMedCrossRef

Kranaster, L., Hoyer, C., Aksay, S. S., Bumb, J. M., Leweke, F. M., Janke, C., et al. (2017). Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: A preliminary prospective study. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-017-0789-7.PubMed

Kraszula, L., Jasinska, A., Eusebio, M., Kuna, P., Glabinski, A., & Pietruczuk, M. (2012). Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurologia i Neurochirurgia Polska, 46(1), 22–28.PubMedCrossRef

Kurajoh, M., Kadoya, M., Morimoto, A., Naka, M., Miyoshi, A., Kanzaki, A., et al. (2016). Plasma leptin concentration is associated with fatigue severity in patients with cardiovascular risk factors—HSCAA study. Psychoneuroendocrinology, 74, 7–12. https://doi.org/10.1016/j.psyneuen.2016.08.016.PubMedCrossRef

Kurban, S., Akpinar, Z., & Mehmetoglu, I. (2008). Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Multiple Sclerosis Journal, 14(3), 431–432. https://doi.org/10.1177/1352458507084028.PubMedCrossRef

Kusminski, C. M., McTernan, P. G., Schraw, T., Kos, K., O’Hare, J. P., Ahima, R., et al. (2007). Adiponectin complexes in human cerebrospinal fluid: Distinct complex distribution from serum. Diabetologia, 50(3), 634–642. https://doi.org/10.1007/s00125-006-0577-9.PubMedCrossRef

Labuz-Roszak, B., & Pierzchala, K. (2007). Difficulties in the diagnosis of autonomic dysfunction in multiple sclerosis. Clinical Autonomic Research, 17(6), 375–377. https://doi.org/10.1007/s10286-007-0443-y.PubMedCrossRef

Laursen, J. H., Sondergaard, H. B., Sorensen, P. S., Sellebjerg, F., & Oturai, A. B. (2016). Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 10, 169–173. https://doi.org/10.1016/j.msard.2016.10.005.PubMedCrossRef

Leo, R., Di Lorenzo, G., Tesauro, M., Cola, C., Fortuna, E., Zanasi, M., et al. (2006). Decreased plasma adiponectin concentration in major depression. Neuroscience Letters, 407(3), 211–213. https://doi.org/10.1016/j.neulet.2006.08.043.PubMedCrossRef

Liu, J., Guo, M., Zhang, D., Cheng, S. Y., Liu, M., Ding, J., et al. (2012). Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proceedings of the National Academy of Sciences USA, 109(30), 12248–12253. https://doi.org/10.1073/pnas.1202835109.CrossRef

Lundberg, J. M., Terenius, L., Hokfelt, T., Martling, C. R., Tatemoto, K., Mutt, V., et al. (1982). Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiologica Scandinavica, 116(4), 477–480. https://doi.org/10.1111/j.1748-1716.1982.tb07171.x.PubMedCrossRef

Maeda, K., Yasuda, M., Kaneda, H., Maeda, S., & Yamadori, A. (1994). Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides, 27(6), 323–332.PubMedCrossRef

Maetani, M., Maskarinec, G., Franke, A. A., & Cooney, R. V. (2009). Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutrition and Cancer, 61(2), 225–231. https://doi.org/10.1080/01635580802455149.PubMedPubMedCentralCrossRef

Mahovic, D., & Lakusic, N. (2007). Progressive impairment of autonomic control of heart rate in patients with multiple sclerosis. Archives of Medical Research, 38(3), 322–325. https://doi.org/10.1016/j.arcmed.2006.11.009.PubMedCrossRef

Mann, M. C., Exner, D. V., Hemmelgarn, B. R., Sola, D. Y., Turin, T. C., Ellis, L., et al. (2013). Vitamin D levels are associated with cardiac autonomic activity in healthy humans. Nutrients, 5(6), 2114–2127. https://doi.org/10.3390/nu5062114.PubMedPubMedCentralCrossRef

Mann, M. C., Exner, D. V., Hemmelgarn, B. R., Turin, T. C., Sola, D. Y., Ellis, L., et al. (2014). Vitamin D supplementation is associated with improved modulation of cardiac autonomic tone in healthy humans. International Journal of Cardiology, 172(2), 506–508. https://doi.org/10.1016/j.ijcard.2014.01.058.PubMedCrossRef

Mao, P. (2011). Potential antidepressant role of neurotransmitter CART: Implications for mental disorders. Depression Research and Treatment, 2011, 762139. https://doi.org/10.1155/2011/762139.PubMedPubMedCentralCrossRef

Mark, A. L., Rahmouni, K., Correia, M., & Haynes, W. G. (2003). A leptin-sympathetic-leptin feedback loop: Potential implications for regulation of arterial pressure and body fat. Acta Physiologica Scandinavica, 177(3), 345–349. https://doi.org/10.1046/j.1365-201X.2003.01085.x.PubMedCrossRef

Marrie, R. A., Cutter, G., Tyry, T., & Vollmer, T. (2009). A cross-sectional study of bone health in multiple sclerosis. Neurology, 73(17), 1394–1398. https://doi.org/10.1212/WNL.0b013e3181beece8.PubMedPubMedCentralCrossRef

Matarese, G., Carrieri, P. B., La Cava, A., Perna, F., Sanna, V., De Rosa, V., et al. (2005). Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proceedings of the National Academy of Sciences USA, 102(14), 5150–5155. https://doi.org/10.1073/pnas.0408995102.CrossRef

Meisinger, C., Heier, M., Lang, O., & Doring, A. (2007). Beta-blocker use and risk of fractures in men and women from the general population: The MONICA/KORA Augsburg cohort study. Osteoporosis International, 18(9), 1189–1195. https://doi.org/10.1007/s00198-007-0354-8.PubMedCrossRef

Miao, J., Shen, L. H., Tang, Y. H., Wang, Y. T., Tao, M. X., Jin, K. L., et al. (2013). Overexpression of adiponectin improves neurobehavioral outcomes after focal cerebral ischemia in aged mice. CNS Neuroscience & Therapeutics, 19(12), 969–977. https://doi.org/10.1111/cns.12198.CrossRef

Miyasaka, N., Akiyoshi, M., & Kubota, T. (2014). Relationship between autonomic nervous system activity and bone mineral density in non-medicated perimenopausal women. Journal of Bone and Mineral Metabolism, 32(5), 588–592. https://doi.org/10.1007/s00774-013-0534-x.PubMedCrossRef

Mokhtarzade, M., Ranjbar, R., Majdinasab, N., Patel, D., & Molanouri Shamsi, M. (2017). Effect of aerobic interval training on serum IL-10, TNFalpha, and adipokines levels in women with multiple sclerosis: Possible relations with fatigue and quality of life. Endocrine, 57(2), 262–271. https://doi.org/10.1007/s12020-017-1337-y.PubMedCrossRef

Morales-Medina, J. C., Dumont, Y., & Quirion, R. (2010). A possible role of neuropeptide Y in depression and stress. Brain Research, 1314, 194–205. https://doi.org/10.1016/j.brainres.2009.09.077.PubMedCrossRef

Morash, B., Li, A., Murphy, P. R., Wilkinson, M., & Ur, E. (1999). Leptin gene expression in the brain and pituitary gland. Endocrinology, 140(12), 5995–5998. https://doi.org/10.1210/endo.140.12.7288.PubMedCrossRef

Mowry, E. M., Waubant, E., McCulloch, C. E., Okuda, D. T., Evangelista, A. A., Lincoln, R. R., et al. (2012). Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Annals of Neurology, 72(2), 234–240. https://doi.org/10.1002/ana.23591.PubMedPubMedCentralCrossRef

Musabak, U., Demirkaya, S., Genc, G., Ilikci, R. S., & Odabasi, Z. (2011). Serum adiponectin, TNF-alpha, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. NeuroImmunoModulation, 18(1), 57–66. https://doi.org/10.1159/000317393.PubMedCrossRef

Nagao, M., Feinstein, T. N., Ezura, Y., Hayata, T., Notomi, T., Saita, Y., et al. (2011). Sympathetic control of bone mass regulated by osteopontin. Proceedings of the National Academy of Sciences USA, 108(43), 17767–17772. https://doi.org/10.1073/pnas.1109402108.CrossRef

Neumeier, M., Weigert, J., Buettner, R., Wanninger, J., Schaffler, A., Muller, A. M., et al. (2007). Detection of adiponectin in cerebrospinal fluid in humans. American journal of physiology. Endocrinology and metabolism, 293(4), E965–E969. https://doi.org/10.1152/ajpendo.00119.2007.PubMedCrossRef

Nieves, J., Cosman, F., Herbert, J., Shen, V., & Lindsay, R. (1994). High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology, 44(9), 1687–1692.PubMedCrossRef

Obuchowicz, E., Krysiak, R., & Herman, Z. S. (2004). Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs? Neuroscience and Biobehavioral Reviews, 28(6), 595–610. https://doi.org/10.1016/j.neubiorev.2004.08.006.PubMedCrossRef

Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences USA, 103(3), 696–701. https://doi.org/10.1073/pnas.0504187103.CrossRef

Ometto, F., Stubbs, B., Annweiler, C., Duval, G. T., Jang, W., Kim, H. T., et al. (2016). Hypovitaminosis D and orthostatic hypotension: A systematic review and meta-analysis. Journal of Hypertension, 34(6), 1036–1043. https://doi.org/10.1097/HJH.0000000000000907.PubMedCrossRef

Oury, F., Khrimian, L., Denny, C. A., Gardin, A., Chamouni, A., Goeden, N., et al. (2013). Maternal and offspring pools of osteocalcin influence brain development and functions. Cell, 155(1), 228–241. https://doi.org/10.1016/j.cell.2013.08.042.PubMedCrossRef

Oury, F., Yadav, V. K., Wang, Y., Zhou, B., Liu, X. S., Guo, X. E., et al. (2010). CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes & Development, 24(20), 2330–2342. https://doi.org/10.1101/gad.1977210.CrossRef

Pasco, J. A., Henry, M. J., Sanders, K. M., Kotowicz, M. A., Seeman, E., Nicholson, G. C., et al. (2004). Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. Journal of Bone and Mineral Research, 19(1), 19–24. https://doi.org/10.1359/JBMR.0301214.PubMedCrossRef

Patti, A., Gennari, L., Merlotti, D., Dotta, F., & Nuti, R. (2013). Endocrine actions of osteocalcin. International Journal of Endocrinology, 2013, 846480. https://doi.org/10.1155/2013/846480.PubMedPubMedCentralCrossRef

Peeyush Kumar, T., Paul, J., Antony, S., & Paulose, C. S. (2011). Expression of cholinergic, insulin, vitamin D receptors and GLUT 3 in the brainstem of streptozotocin induced diabetic rats: Effect of treatment with vitamin D(3). Neurochemical Research, 36(11), 2116–2126. https://doi.org/10.1007/s11064-011-0536-9.PubMedCrossRef

Penesova, A., Vlcek, M., Imrich, R., Vernerova, L., Marko, A., Meskova, M., et al. (2015). Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metabolic Brain Disease, 30(4), 895–901. https://doi.org/10.1007/s11011-015-9665-1.PubMedCrossRef

Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Handbook of Experimental Pharmacology, (168), 1–51.

Piccio, L., Cantoni, C., Henderson, J. G., Hawiger, D., Ramsbottom, M., Mikesell, R., et al. (2013). Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. European Journal of Immunology, 43(8), 2089–2100. https://doi.org/10.1002/eji.201242836.PubMedPubMedCentralCrossRef

Pisanu, C., Preisig, M., Castelao, E., Glaus, J., Cunningham, J. L., Del Zompo, M., et al. (2017). High leptin levels are associated with migraine with aura. Cephalalgia, 37(5), 435–441. https://doi.org/10.1177/0333102416648650.PubMedCrossRef

Polak, G., Strozecki, P., Grzesk, G., Manitius, J., Grabczewska, Z., & Przybyl, R. (2004). Effect of parathormone on heart rate variability in hemodialysis patients. Autonomic Neuroscience: Basic and Clinical, 115(1–2), 94–98. https://doi.org/10.1016/j.autneu.2004.08.002.CrossRef

Popovic, M., Stanojevic, Z., Tosic, J., Isakovic, A., Paunovic, V., Petricevic, S., et al. (2015). Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats. Journal of Neurochemistry, 135(1), 125–138. https://doi.org/10.1111/jnc.13198.PubMedCrossRef

Puig, J., Blasco, G., Daunis-i-Estadella, J., Moreno, M., Molina, X., Alberich-Bayarri, A., et al. (2016). Lower serum osteocalcin concentrations are associated with brain microstructural changes and worse cognitive performance. Clinical Endocrinology Oxford, 84(5), 756–763. https://doi.org/10.1111/cen.12954.PubMedCrossRef

Qiu, G., Wan, R., Hu, J., Mattson, M. P., Spangler, E., Liu, S., et al. (2011). Adiponectin protects rat hippocampal neurons against excitotoxicity. Age (Dordr), 33(2), 155–165. https://doi.org/10.1007/s11357-010-9173-5.CrossRef

Rao, R. R., Randeva, H. S., Sankaranarayanan, S., Narashima, M., Mohlig, M., Mehanna, H., et al. (2012). Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocrine Connections, 1(1), 13–21. https://doi.org/10.1530/EC-12-0008.PubMedPubMedCentralCrossRef

Redrobe, J. P., Dumont, Y., Fournier, A., Baker, G. B., & Quirion, R. (2005). Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides, 26(8), 1394–1400. https://doi.org/10.1016/j.peptides.2005.03.029.PubMedCrossRef

Reid, I. R., Gamble, G. D., Grey, A. B., Black, D. M., Ensrud, K. E., Browner, W. S., et al. (2005). beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. Journal of Bone and Mineral Research, 20(4), 613–618. https://doi.org/10.1359/JBMR.041202.PubMedCrossRef

Rejnmark, L., Vestergaard, P., Kassem, M., Christoffersen, B. R., Kolthoff, N., Brixen, K., et al. (2004). Fracture risk in perimenopausal women treated with beta-blockers. Calcified Tissue International, 75(5), 365–372. https://doi.org/10.1007/s00223-004-0222-x.PubMedCrossRef

Rodan, G. A., & Martin, T. J. (2000). Therapeutic approaches to bone diseases. Science, 289(5484), 1508–1514.PubMedCrossRef

Rosen, C. J. (2009). Serotonin rising–the bone, brain, bowel connection. New England Journal of Medicine, 360(10), 957–959. https://doi.org/10.1056/NEJMp0810058.PubMedCrossRef

Rothem, D. E., Rothem, L., Soudry, M., Dahan, A., & Eliakim, R. (2009). Nicotine modulates bone metabolism-associated gene expression in osteoblast cells. Journal of Bone and Mineral Metabolism, 27(5), 555–561. https://doi.org/10.1007/s00774-009-0075-5.PubMedCrossRef

Rudang, R., Darelid, A., Nilsson, M., Nilsson, S., Mellstrom, D., Ohlsson, C., et al. (2012). Smoking is associated with impaired bone mass development in young adult men: A 5-year longitudinal study. Journal of Bone and Mineral Research, 27(10), 2189–2197. https://doi.org/10.1002/jbmr.1674.PubMedCrossRef

Sanchez Lopez, A. J., Roman-Vega, L., Ramil Tojeiro, E., Giuffrida, A., & Garcia-Merino, A. (2015). Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-beta: A longitudinal study in multiple sclerosis patients. Clinical and Experimental Immunology, 179(1), 119–127. https://doi.org/10.1111/cei.12443.PubMedCrossRef

Sanchez-Margalet, V., Martin-Romero, C., Santos-Alvarez, J., Goberna, R., Najib, S., & Gonzalez-Yanes, C. (2003). Role of leptin as an immunomodulator of blood mononuclear cells: Mechanisms of action. Clinical and Experimental Immunology, 133(1), 11–19.PubMedPubMedCentralCrossRef

Sandberg, L., Bistrom, M., Salzer, J., Vagberg, M., Svenningsson, A., & Sundstrom, P. (2016). Vitamin D and axonal injury in multiple sclerosis. Multiple Sclerosis Journal, 22(8), 1027–1031. https://doi.org/10.1177/1352458515606986.PubMedCrossRef

Sandyk, R. (1998). Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. International Journal of Neuroscience, 95(1–2), 133–140.PubMedCrossRef

Sanna, V., Di Giacomo, A., La Cava, A., Lechler, R. I., Fontana, S., Zappacosta, S., et al. (2003). Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. The Journal of Clinical Investigation, 111(2), 241–250. https://doi.org/10.1172/JCI16721.PubMedPubMedCentralCrossRef

Sanya, E. O., Tutaj, M., Brown, C. M., Goel, N., Neundorfer, B., & Hilz, M. J. (2005). Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients. Clinical Autonomic Research, 15(3), 213–218. https://doi.org/10.1007/s10286-005-0274-7.PubMedCrossRef

Schafer, A. L., Sellmeyer, D. E., Schwartz, A. V., Rosen, C. J., Vittinghoff, E., Palermo, L., et al. (2011). Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: Parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). Journal of Clinical Endocrinology and Metabolism, 96(12), E1982–E1989. https://doi.org/10.1210/jc.2011-0587.PubMedPubMedCentralCrossRef

Schmitt, C. P., Obry, J., Feneberg, R., Veldhuis, J. D., Mehls, O., Ritz, E., et al. (2003). Beta1-adrenergic blockade augments pulsatile PTH secretion in humans. Journal of the American Society of Nephrology, 14(12), 3245–3250.PubMedCrossRef

Schmitt, C. P., Schaefer, F., Bruch, A., Veldhuis, J. D., Schmidt-Gayk, H., Stein, G., et al. (1996). Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. Journal of Clinical Endocrinology and Metabolism, 81(12), 4236–4243. https://doi.org/10.1210/jcem.81.12.8954021.PubMed

Shelton, R. C., Falola, M., Li, L., Zajecka, J., Fava, M., & Papakostas, G. I. (2015). The pro-inflammatory profile of depressed patients is (partly) related to obesity. Journal of Psychiatric Research, 70, 91–97. https://doi.org/10.1016/j.jpsychires.2015.09.001.PubMedPubMedCentralCrossRef

Shi, Y., Oury, F., Yadav, V. K., Wess, J., Liu, X. S., Guo, X. E., et al. (2010). Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metabolism, 11(3), 231–238. https://doi.org/10.1016/j.cmet.2010.01.005.PubMedPubMedCentralCrossRef

Shohami, E., & Mechoulam, R. (2006). Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proceedings of the National Academy of Sciences USA, 103(16), 6087–6088. https://doi.org/10.1073/pnas.0601847103.CrossRef

Singh, M. K., Elefteriou, F., & Karsenty, G. (2008). Cocaine and amphetamine-regulated transcript may regulate bone remodeling as a circulating molecule. Endocrinology, 149(8), 3933–3941. https://doi.org/10.1210/en.2008-0109.PubMedPubMedCentralCrossRef

Smolders, J., Schuurman, K. G., van Strien, M. E., Melief, J., Hendrickx, D., Hol, E. M., et al. (2013). Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. Journal of Neuropathology and Experimental Neurology, 72(2), 91–105. https://doi.org/10.1097/NEN.0b013e31827f4fcc.PubMedCrossRef

Soilu-Hanninen, M., Laaksonen, M., Laitinen, I., Eralinna, J. P., Lilius, E. M., & Mononen, I. (2008). A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 79(2), 152–157. https://doi.org/10.1136/jnnp.2006.105320.PubMedCrossRef

Solaro, C., Bergamaschi, R., Rezzani, C., Mueller, M., Trabucco, E., Bargiggia, V., et al. (2013). Duloxetine is effective in treating depression in multiple sclerosis patients: An open-label multicenter study. Clinical Neuropharmacology, 36(4), 114–116. https://doi.org/10.1097/WNF.0b013e3182996400.PubMedCrossRef

Steffensen, L. H., Jorgensen, L., Straume, B., Mellgren, S. I., & Kampman, M. T. (2011). Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology, 258(9), 1624–1631. https://doi.org/10.1007/s00415-011-5980-6.PubMedPubMedCentralCrossRef

Stepan, J. J., Havrdova, E., Tyblova, M., Horakova, D., Ticha, V., Novakova, I., et al. (2004). Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clinica Chimica Acta, 348(1–2), 147–154. https://doi.org/10.1016/j.cccn.2004.05.012.CrossRef

Sternberg, Z. (2012). Sympathetic nervous system dysfunction in multiple sclerosis, linking neurodegeneration to a reduced response to therapy. Current Pharmaceutical Design, 18(12), 1635–1644.PubMedCrossRef

Sternberg, Z. (2015). Promoting sympathovagal balance in multiple sclerosis; pharmacological, non-pharmacological, and surgical strategies. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2015.04.012.PubMed

Sternberg, Z., Leung, C., Sternberg, D., Li, F., Karmon, Y., Chadha, K., et al. (2013). The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients. CNS & Neurological Disorders: Drug Targets, 12(1), 104–111.CrossRef

Suzuki, Y., Shimizu, H., Ishizuka, N., Kubota, N., Kubota, T., Senoo, A., et al. (2014). Vagal hyperactivity due to ventromedial hypothalamic lesions increases adiponectin production and release. Diabetes, 63(5), 1637–1648. https://doi.org/10.2337/db13-0636.PubMedCrossRef

Tabesh, M., Azadbakht, L., Faghihimani, E., Tabesh, M., & Esmaillzadeh, A. (2014). Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: A randomized controlled clinical trial. Journal of Clinical Endocrinology and Metabolism, 99(12), E2485–E2493. https://doi.org/10.1210/jc.2014-1977.PubMedCrossRef

Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., et al. (2002). Leptin regulates bone formation via the sympathetic nervous system. Cell, 111(3), 305–317.PubMedCrossRef

Tam, J., Trembovler, V., Di Marzo, V., Petrosino, S., Leo, G., Alexandrovich, A., et al. (2008). The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. The FASEB Journal, 22(1), 285–294. https://doi.org/10.1096/fj.06-7957com.PubMedCrossRef

Tang, B. L. (2008). Leptin as a neuroprotective agent. Biochemical and Biophysical Research Communications, 368(2), 181–185. https://doi.org/10.1016/j.bbrc.2008.01.063.PubMedCrossRef

Tariq, S., Tariq, S., Alam, S. S., & Baig, M. (2015). Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporosis International, 26(3), 1187–1192. https://doi.org/10.1007/s00198-014-2909-9.PubMedCrossRef

Tenta, R., Panagiotakos, D. B., Fragopoulou, E., Nomikos, T., Pitsavos, C., Chrysohoou, C., et al. (2010). Osteoprotegerin and nuclear factor-kappaB ligand are associated with leptin and adiponectin levels, in apparently healthy women. Journal of Musculoskeletal and Neuronal Interactions, 10(2), 174–179.PubMed

Terzi, T., Terzi, M., Tander, B., Canturk, F., & Onar, M. (2010). Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. Journal of Clinical Neuroscience, 17(10), 1260–1264. https://doi.org/10.1016/j.jocn.2010.01.044.PubMedCrossRef

Tien, D., Ohara, P. T., Larson, A. A., & Jasmin, L. (2003). Vagal afferents are necessary for the establishment but not the maintenance of kainic acid-induced hyperalgesia in mice. Pain, 102(1–2), 39–49.PubMedCrossRef

Uede, T. (2011). Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathology International, 61(5), 265–280. https://doi.org/10.1111/j.1440-1827.2011.02649.x.PubMedCrossRef

Ueno, N., Dube, M. G., Inui, A., Kalra, P. S., & Kalra, S. P. (2004). Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology, 145(9), 4176–4184. https://doi.org/10.1210/en.2004-0262.PubMedCrossRef

van den Bos, F., Speelman, A. D., van Nimwegen, M., van der Schouw, Y. T., Backx, F. J., Bloem, B. R., et al. (2013). Bone mineral density and vitamin D status in Parkinson’s disease patients. Journal of Neurology, 260(3), 754–760. https://doi.org/10.1007/s00415-012-6697-x.PubMedCrossRef

Vogt, M. H., Lopatinskaya, L., Smits, M., Polman, C. H., & Nagelkerken, L. (2003). Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Annals of Neurology, 53(6), 819–822. https://doi.org/10.1002/ana.10606.PubMedCrossRef

Vogt, M. H., ten Kate, J., Drent, R. J., Polman, C. H., & Hupperts, R. (2010). Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Multiple Sclerosis Journal, 16(4), 443–449. https://doi.org/10.1177/1352458509359723.PubMedCrossRef

Walker, L. M., Preston, M. R., Magnay, J. L., Thomas, P. B., & El Haj, A. J. (2001). Nicotinic regulation of c-fos and osteopontin expression in human-derived osteoblast-like cells and human trabecular bone organ culture. Bone, 28(6), 603–608.PubMedCrossRef

Wen, S. R., Liu, G. J., Feng, R. N., Gong, F. C., Zhong, H., Duan, S. R., et al. (2012). Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology, 244(1–2), 94–96. https://doi.org/10.1016/j.jneuroim.2011.12.004.PubMedCrossRef

Williams, G. A., Kukreja, S. C., Longley, R. S., Bowser, E. N., Hargis, G. K., Vora, N. M., et al. (1985). Effect of the parasympathetic system on secretion of parathyroid hormone. Metabolism, 34(7), 612–615.PubMedCrossRef

Wong, P. K., Christie, J. J., & Wark, J. D. (2007). The effects of smoking on bone health. Clinical Science (London), 113(5), 233–241. https://doi.org/10.1042/CS20060173.CrossRef

Wong, I. P., Nguyen, A. D., Khor, E. C., Enriquez, R. F., Eisman, J. A., Sainsbury, A., et al. (2013). Neuropeptide Y is a critical modulator of leptin’s regulation of cortical bone. Journal of Bone and Mineral Research, 28(4), 886–898. https://doi.org/10.1002/jbmr.1786.PubMedCrossRef

Wu, E. L., Chien, I. C., Lin, C. H., Chou, Y. J., & Chou, P. (2013). Increased risk of hypothyroidism and hyperthyroidism in patients with major depressive disorder: A population-based study. Journal of Psychosomatic Research, 74(3), 233–237. https://doi.org/10.1016/j.jpsychores.2012.12.016.PubMedCrossRef

Wu, H., Li, L., & Su, X. (2014). Vagus nerve through alpha7 nAChR modulates lung infection and inflammation: Models, cells, and signals. BioMed Research International, 2014, 283525. https://doi.org/10.1155/2014/283525.PubMedPubMedCentral

Xu, J. Y., & Chen, C. (2014). Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist. https://doi.org/10.1177/1073858414524632.PubMedPubMedCentral

Yadav, V. K., Oury, F., Suda, N., Liu, Z. W., Gao, X. B., Confavreux, C., et al. (2009). A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell, 138(5), 976–989. https://doi.org/10.1016/j.cell.2009.06.051.PubMedPubMedCentralCrossRef

Yadav, V. K., Ryu, J. H., Suda, N., Tanaka, K. F., Gingrich, J. A., Schutz, G., et al. (2008). Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell, 135(5), 825–837. https://doi.org/10.1016/j.cell.2008.09.059.PubMedPubMedCentralCrossRef

Yong, H., Chartier, G., & Quandt, J. (2017). Modulating inflammation and neuroprotection in multiple sclerosis. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.24090.PubMed

Zanatta, L. C., Boguszewski, C. L., Borba, V. Z., & Kulak, C. A. (2014). Osteocalcin, energy and glucose metabolism. Arquivos Brasileiros de Endocrinologia & Metabologia, 58(5), 444–451.CrossRef

Zarkesh-Esfahani, H., Pockley, G., Metcalfe, R. A., Bidlingmaier, M., Wu, Z., Ajami, A., et al. (2001). High-dose leptin activates human leukocytes via receptor expression on monocytes. The Journal of Immunology, 167(8), 4593–4599.PubMedCrossRef

Zeinstra, E., Wilczak, N., & De Keyser, J. (2000). [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neuroscience Letters, 289(1), 75–77.PubMedCrossRef

Zengin, A., Zhang, L., Herzog, H., Baldock, P. A., & Sainsbury, A. (2010). Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends in Endocrinology and Metabolism, 21(7), 411–418. https://doi.org/10.1016/j.tem.2010.02.004.PubMedCrossRef

Zhang, Y., Zhou, P., & Kimondo, J. W. (2012). Adiponectin and osteocalcin: Relation to insulin sensitivity. Biochemistry and Cell Biology, 90(5), 613–620. https://doi.org/10.1139/o2012-022.PubMedCrossRef

Zimmer, A. (2016). A collaboration investigating endocannabinoid signalling in brain and bone. Journal of Basic and Clinical Physiology and Pharmacology, 27(3), 229–235. https://doi.org/10.1515/jbcpp-2015-0125.PubMed

Springer Medizin

Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Behavioral, Biochemical and Molecular Characterization of a Parkinson’s Disease Mouse Model Using the Neurotoxin 2′-CH3-MPTP: A Novel Approach

Vitamin D3 Supplementation Reduces Subsequent Brain Injury and Inflammation Associated with Ischemic Stroke

Correction of Huntington’s Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model

Inhibition of GSK-3beta Signaling Pathway Rescues Ketamine-Induced Neurotoxicity in Neural Stem Cell-Derived Neurons

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies